Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: The Swiss HIV Cohort Study

HIV Medicine

Volumn 12, Issue 5, 2011, Pages 299-307

  Young, J ^a   Scherrer, Au ^b   Günthard, Hf ^b   Opravil, M ^c   Yerly, S ^d   Boni J ^e   Rickenbach, M ^f   Fux, Ca ^g   Cavassini, M ^f   Bernasconi, E ^h   Vernazza, P ⁱ   Hirschel, B ^d   Battegay, M ^j   Bucher, Hc ^a,j  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c KLINIK HIRSLANDEN   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

ⁱ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

Bayes theorem; HIV drug resistance; Protease inhibitors; Risk factors; Salvage therapy; Viral load

Indexed keywords

AMPRENAVIR; DARUNAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SALVAGE THERAPY; SWITZERLAND; TREATMENT FAILURE; VIRUS LOAD;

BAYES THEOREM; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79953284603     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00885.x     Document Type: Article

References (33)

1. Wilson LE, Gallant JE. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin Infect Dis 2009; 48: 214-221.
2. Tremblay CL. Combating HIV resistance - focus on darunavir. Ther Clin Risk Manag 2008; 4: 759-766.
3. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-1178.
4. Madruga JV, Berger D, McMurchie M et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58.
5. Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
6. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007; 60: 1195-1205.
7. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
8. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
9. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-365.
10. De Meyer S, Azijn H, Fransen E et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. Antivir Ther 2006; 11: S24.
11. De Meyer S, Vangeneugden T, Lefebvre E et al. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. Antivir Ther 2006; 11: S83.
12. De Meyer S, Dierynck I, Lathouwers E et al. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2. Antivir Ther 2008; 13: A33.
13. Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 2008; 10: 131-142.
14. Descamps D, Lambert-Niclot S, Marcelin AG et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 2009; 63: 585-592.
15. Poveda E, de Mendoza C, Martin-Carbonero L et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007; 60: 885-888.
16. The Swiss HIV Cohort Study. Cohort profile: the Swiss HIV Cohort Study. Int J Epidemiol 2010; 39: 1179-1189.
17. Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. October 2002. Available at (accessed 20 July 2009).
18. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of HIV Epidemiologic Research Europe (COHERE). Triple class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010; 170: 410-419.
19. von Wyl V, Yerly S, Boni J et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167: 1782-1790.
20. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-145.
21. Carlin JB, Wolfe R, Coffey C, Patton GC. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete-time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat Med 1999; 18: 2655-2679.
22. Greenland S. Prior data for non-normal priors. Stat Med 2007a; 26: 3578-3590.
23. Greenland S. Bayesian perspectives for epidemiological research. II. Regression analysis. Int J Epidemiol 2007b; 36: 195-202.
24. Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc 1995; 90: 773-795.
25. Schmidt UE. Closure of the tipranavir POTENT trial. 9 June 2008. Available at (accessed 10 September 2009).
26. Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol 2006; 35: 765-775.
27. Gill CJ, Sabin L, Schmid CH. Why clinicians are natural bayesians. BMJ 2005; 330: 1080-1083.
28. Moye LA. Bayesians in clinical trials: asleep at the switch. Stat Med 2008; 27: 469-482.
29. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 2004; 66: 411-421.
30. Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epidemiol 2000; 151: 531-539.
31. Pellegrin I, Wittkop L, Joubert LM et al. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther 2008; 13: 271-279.
32. Molto J, Santos JR, Perez-Alvarez N et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008; 52: 3928-3932.
33. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005; 294: 218-228.